Four Artemisinin-Based Treatments in African Pregnant Women with Malaria
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Information regarding the safety and efficacy of artemisinin combination treatments for malaria in pregnant women is limited, particularly among women who live in sub-Saharan Africa. METHODS: We conducted a multicenter, randomized, open-label trial of treatments for malaria in pregnant women in four African countries. A total of 3428 pregnant women in the second or third trimester who had falciparum malaria (at any parasite density and regardless of symptoms) were treated with artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate, or dihydroartemisinin-piperaquine. The primary end points were the polymerase-chain-reaction (PCR)-adjusted cure rates (i.e., cure of the original infection; new infections during follow-up were not considered to be treatment failures) at day 63 and safety outcomes. RESULTS: The PCR-adjusted cure rates in the per-protocol analysis were 94.8% in the artemether-lumefantrine group, 98.5% in the amodiaquine-artesunate group, 99.2% in the dihydroartemisinin-piperaquine group, and 96.8% in the mefloquine-artesunate group; the PCR-adjusted cure rates in the intention-to-treat analysis were 94.2%, 96.9%, 98.0%, and 95.5%, respectively. There was no significant difference among the amodiaquine-artesunate group, dihydroartemisinin-piperaquine group, and the mefloquine-artesunate group. The cure rate in the artemether-lumefantrine group was significantly lower than that in the other three groups, although the absolute difference was within the 5-percentage-point margin for equivalence. The unadjusted cure rates, used as a measure of the post-treatment prophylactic effect, were significantly lower in the artemether-lumefantrine group (52.5%) than in groups that received amodiaquine-artesunate (82.3%), dihydroartemisinin-piperaquine (86.9%), or mefloquine-artesunate (73.8%). No significant difference in the rate of serious adverse events and in birth outcomes was found among the treatment groups. Drug-related adverse events such as asthenia, poor appetite, dizziness, nausea, and vomiting occurred significantly more frequently in the mefloquine-artesunate group (50.6%) and the amodiaquine-artesunate group (48.5%) than in the dihydroartemisinin-piperaquine group (20.6%) and the artemether-lumefantrine group (11.5%) (P<0.001 for comparison among the four groups). CONCLUSIONS: Artemether-lumefantrine was associated with the fewest adverse effects and with acceptable cure rates but provided the shortest post-treatment prophylaxis, whereas dihydroartemisinin-piperaquine had the best efficacy and an acceptable safety profile. (Funded by the European and Developing Countries Clinical Trials Partnership and others; ClinicalTrials.gov number, NCT00852423.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takem, E. N., & D'Alessandro, U. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.010 · Cited by 185
McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050253 · Cited by 136
Piola, P., Nabasumba, C., Turyakira, E., Dhorda, M., Lindegardh, N., Nyehangane, D., Snounou, G., Ashley, E. A., McGready, R., Nosten, F., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70202-4 · Cited by 99
Manyando, C., Kayentao, K., D’Alessandro, U., Okafor, H. U., Juma, E., & Hamed, K. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-141 · Cited by 62
Rijken, M. J., McGready, R., Jullien, V., Tarning, J., Lindegardh, N., Phyo, A. P., Win, A. K., Hsi, P., Cammas, M., Singhasivanon, P., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00154-11 · Cited by 50
Cited by
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
Fried, M., & Duffy, P. E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025551 · Cited by 202
An overview of malaria in pregnancy
Bauserman, M., Conroy, A. L., North, K., Patterson, J., Bose, C., & Meshnick, S. (2019) · Seminars in Perinatology · doi:10.1053/j.semperi.2019.03.018 · Cited by 167
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines
Al Khaja, K. A. J., & Sequeira, R. P. (2021) · Malaria Journal · doi:10.1186/s12936-020-03565-2 · Cited by 39
Saito, M., Carrara, V. I., Gilder, M. E., Min, A. M., Tun, N. W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Haohankhunnatham, W., Konghahong, K., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02002-8 · Cited by 25
Metadata
- Authors
- The PREGACT Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-10
- Volume
- 374
- Issue
- 10
- Pages
- 913-927
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2404868509
- Cited by
- 99
- References
- 5
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. https://app.cochat.ai/papers/10.1056/nejmoa1508606
- The paper
- The PREGACT Study Group. (2016). Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1508606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.